Mark Fishman, Novartis

Mark Fishman, Novartis ($NVS)
2012 Pay Package: $8.81 million
2011 Pay Package: $8.49 million
Change: +3.77%
2012 Compensation: $990,000 in salary; $23,265 in incentive pay; $4.93 million in share grants; $1.55 million in performance shares; $242,832 in pension growth; $118,319 in other benefits; and $966,736 in future matching funds for an employee stock ownership plan

As one of biopharma's biggest R&D spenders, Novartis runs multiple programs in multiple therapeutic areas, using a tried-and-true, thin-end-of-the-wedge strategy. It aims for new drug approvals in small groups of patients, and then expands from there, indication by indication. Consider everolimus, approved in 2009 under the brand name Afinitor, to treat patients with advanced kidney cancer who had failed on one other biologic treatment. Since then, it has gathered up uses in patients with kidney transplants (as Zortress), pancreatic tumors, liver transplants and, most recently, breast cancer, a use that could add $1.5 billion to peak sales.

Along the way, Afinitor sales have soared, from $243 million in 2010 to $797 million last year--and it is obviously one drug in which Novartis is highly invested. But just like its R&D strategy, Novartis isn't putting all its eggs in one basket. Last fall Novartis tapped secukinumab as one of 14 leading drug hopefuls in an industry-leading late-stage pipeline, an impressive lineup for a pharma giant that spends an industry-leading $9.5 billion a year on R&D. And just weeks ago the drug beat Enbrel in a head-to-head showdown on psoriasis. Its COPD drug Ultibro Breezhaler just gained an endorsement from the European Committee for Medicinal Products for Human Use (CHMP), and Bloomberg recently reported that Novartis is interested in finding a competitive Alzheimer's drug program.

Before joining Novartis as president of the Novartis Institutes for BioMedical Research in 2002, Fishman was chief of cardiology and director of the Cardiovascular Research Center at Massachusetts General Hospital and professor of medicine at Harvard Medical School.

For more:
Novartis grabs lead IL-17 program as Ensemble adds another marquee deal
Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown
Novartis' $600M R&D campus in Boston taking form amid cutbacks elsewhere

-- Emily Mullin

Mark Fishman, Novartis
Read more on

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.